Monte Rosa Therapeutics (GLUE) Stock Analysis & AI Equity Report
Monte Rosa Therapeutics (GLUE) overview
Monte Rosa Therapeutics (GLUE) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 124m and operating profit of USD -54.2m; the year-end share price was 15.68 USD and market capitalisation was USD 1,028m. Monte Rosa Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Monte Rosa Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Monte Rosa Therapeutics
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing small-molecule molecular glue degraders designed to direct selected proteins for degradation. Its discovery platform combines artificial intelligence and machine learning with proprietary experimental tools to identify targets and develop drug candidates. Its clinical programs address immune-mediated, inflammatory, and cancer diseases; Novartis holds an exclusive license for its VAV1-directed program.
Generate the Monte Rosa Therapeutics report
Monte Rosa Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Monte Rosa Therapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Monte Rosa Therapeutics
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.